Fig. 3

Ru1 halts PDAC, CRC and OS PDX growth in vivo. A Left: Average fold change in tumor volume ± SEM in mice bearing Panc185 PDXs and treated with Ru1 orally (o.g.), intra tumoral (i.t.) or retro orbitally (r.o.) over the course of 21 days and compared to d0 (n=4-6 tumors/group). Right: Fold change in tumor volume ± SEM determined on day 21 post treatment initiation. *p < 0.05; ns= not significant, as determined by one-way ANOVA with Dunnett post-test, compared to oral. B Experimental set-up for in vivo experiments using subcutaneously or orthotopically implanted PDXs and treatment with Ru1 (1.4 mg/kg; daily) and/or Gemcitabine (50mg/kg; twice per week). C Average fold change in tumor volume ± SEM in mice bearing Panc215 PDXs (left) or Panc354 PDXs (right) and treated with diluent control (Ctl), Ru1 (1.4mg/kg r.o.; daily), Gemcitabine (50mg/kg; twice per week) or a combination of both and compared to d0 (n=6-8 tumors/group). Histograms: Fold change in tumor volume ± SEM determined at treatment cessation. *p < 0.05, **p < 0.01, *** p<0.001, **** p<0.0001, as determined by one-way ANOVA with Dunnett post-test, compared to Ctl. D Mean percentage of EpCAM+, EpCAM+/CD133+, or EpCAM+/CD133+/CXCR4+ PaCSCs ± SEM, determined by flow cytometry, in extracted Panc354 tumors from (C). *** p<0.001, as determined by unpaired two-sided Student’s t-test. E Picomoles of Ru1 per mg of tumor, determined by ICP-MS, from PDX354 tumors extracted on d19 post treatment initiation (approx. 30-32h after the final injection). F Left: Average fold change in tumor volume ± SEM in mice bearing CRC01 treated with diluent control (Ctl), Ru1 (1.4mg/kg r.o.; daily), 5FU (30mg/kg; twice per week) or a combination of both and compared to d0 (n=8-12 tumors/group). Right: Fold change in tumor volume ± SEM determined at treatment cessation (d16). *p < 0.05; ns= not significant, as determined by one-way ANOVA with Dunnett post-test, compared to Ctl. G Left: Average fold change in tumor volume ± SEM in mice bearing OS170921 treated with diluent control (Ctl) or Ru1 (daily 1.4mg/kg r.o) and compared to d0 (n=6-8 tumors/group). Right: Fold change in tumor volume ± SEM determined at treatment cessation (d57). **p < 0.01, as determined by unpaired two-sided Student’s t-test. H OS170921 tumor weights (g) ± SEM determined at treatment cessation (d57). *p < 0.05, as determined by unpaired two-sided Student’s t-test